Literature DB >> 8306073

5-HT3 antagonists reduce morphine self-administration in rats.

S C Hui1, E L Sevilla, C W Ogle.   

Abstract

1. The effects of the 5-HT3 receptor antagonists, ondansetron and tropisetron, on morphine consumption were studied in naive and morphine-dependent rats. 2. The administration of ondansetron (1 microgram kg-1, i.p. twice daily) 7 days prior to, and during a 21-day period of, morphine availability (increasing concentration from 0.1 to 0.4 mg ml-1) in 5% sucrose solution reduced opiate intake from the 9th day of morphine treatment. 3. The administration of ondansetron (0.1 microgram kg-1, i.p. twice daily) or tropisetron (0.1 microgram kg-1, i.p. twice daily) on the 14th day of the 21-day period of morphine treatment failed to reduce opiate consumption. Administration of the larger doses of tropisetron (1 microgram kg-1) or ondansetron (1 microgram kg-1) reduced morphine consumption. 4. After receiving 21 days of treatment with morphine alone or with the ondansetron or tropisetron regimens identified above, the sucrose solutions were substituted with tap water for 7 days. These detoxified rats were then allowed a free choice of sucrose or morphine for 10 days. Animals that had received concomitant treatment with ondansetron or tropisetron showed reduced morphine intake when compared with the controls treated with morphine only or with vehicle-treated controls. 5. The administration of cyproheptadine (100 or 250 micrograms kg-1, i.p. twice daily) on the 14th day of 21-day morphine treatment failed to modify morphine intake and also failed to influence the subsequent intake of the opiate in the free choice situation. 6. It is concluded that ondasetron and tropisetron can reduce morphine intake in both naive and morphine-dependent rats.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306073      PMCID: PMC2175894          DOI: 10.1111/j.1476-5381.1993.tb13966.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Depression of morphine-seeking behaviour by dopamine inhibition.

Authors:  A S Schwartz; P L Marchok
Journal:  Nature       Date:  1974-03-15       Impact factor: 49.962

2.  Self-administration of methionine enkephalin into the nucleus accumbens.

Authors:  N E Goeders; J D Lane; J E Smith
Journal:  Pharmacol Biochem Behav       Date:  1984-03       Impact factor: 3.533

3.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

4.  Heroin reward is dependent on a dopaminergic substrate.

Authors:  M A Bozarth; R A Wise
Journal:  Life Sci       Date:  1981-11-02       Impact factor: 5.037

5.  Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens.

Authors:  J P Chen; H M van Praag; E L Gardner
Journal:  Brain Res       Date:  1991-03-15       Impact factor: 3.252

6.  Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats.

Authors:  H O Pettit; A Ettenberg; F E Bloom; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems.

Authors:  A Ettenberg; H O Pettit; F E Bloom; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Morphine preference in rats previously morphine dependent.

Authors:  S Dai; S C Hui; C W Ogle
Journal:  Pharmacol Res Commun       Date:  1984-05

9.  Reinforcing effects of morphine in the nucleus accumbens.

Authors:  M E Olds
Journal:  Brain Res       Date:  1982-04-15       Impact factor: 3.252

10.  Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system.

Authors:  C Spyraki; H C Fibiger; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more
  9 in total

Review 1.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice.

Authors:  De-Yong Liang; XiangQi Li; J David Clark
Journal:  Anesthesiology       Date:  2011-05       Impact factor: 7.892

Review 3.  Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.

Authors:  Tina K Machu
Journal:  Pharmacol Ther       Date:  2011-02-26       Impact factor: 12.310

4.  Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors.

Authors:  P De Deurwaerdère; L Stinus; U Spampinato
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

Review 5.  The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.

Authors:  E A Engleman; Z A Rodd; R L Bell; J M Murphy
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

6.  Morphine induced changes in ethanol-and water-intake are attenuated by the 5-HT3/4 antagonist tropisetron (ICS 205-930).

Authors:  C W Hodge; J S Niehus; H H Samson
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

7.  Prevention by the 5-HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the rat.

Authors:  S C Hui; E L Sevilla; C W Ogle
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 8.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

9.  5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders.

Authors:  Shvetank Bhatt; Thangaraj Devadoss; Santhepete Nanjundaiah Manjula; Jayaraman Rajangam
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.